Business
Saskatchewan Adds CAPVAXIVE® to Publicly Funded Adult Immunization Program
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly funded adult immunization program. This addition supports increased access to pneumococcal immunization for eligible adults in accordance with the provincial eligibility criteria.
About this update from Merck & Company, Inc.
[{"type":"text","content":"KIRKLAND, QC, Dec. 8, 2025 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly funded adult immunization program. This addition supports increased access to pneumococcal immunization for eligible adults in accordance with the provincial eligibility criteria.","length":429,"tagName":"p"},{"type":"image","alt":"Merck Logo (PRNewsfoto/Merck)","displaySize":"","headline":null,"caption":"Merck Logo (PRNewsfoto/Merck)","className":"","disableSlideshowImg":false,"size":{"original":{"width":148,"height":44,"url":"https://media.zenfs.com/en/cnwgroup.com/a31c818593c897369fcfa7d3a78ada87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WPGiatRLHK00PDoDVoPplg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/cnwgroup.com/a31c818593c897369fcfa7d3a78ada87","width":148,"height":44}},"href":"https://mma.prnewswire.com/media/2814415/Merck_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"CAPVAXIVE® is approved by Health Canada for adults 18+ to help prevent invasive pneumococcal disease (IPD)—including serious infections like sepsis, meningitis, and bacteremic pneumonia—caused by 21 Streptococcus pneumoniae serotypes. Surveillance data from the Public Health Agency of Canada (2019–2023) showed that these serotypes accounted for approximately:","length":361,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"65% of IPD cases in adults aged 18–49","length":37,"tagName":"p"}]},{"val":[{"type":"text","content":"74% of IPD cases in adults aged 50–64","length":37,"tagName":"p"}]},{"val":[{"type":"text","content":"80% of IPD cases in adults aged 65+","length":35,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":109,"olType":false},{"type":"text","content":"These figures were based on surveillance data and do not reflect the efficacy of CAPVAXIVE®.","length":92,"tagName":"p"},{"type":"text","content":"Saskatchewan's decision is informed by the recommendations from the National Advisory Committee on Immunization (NACI), which supports CAPVAXIVE® as an option for adults 65+ and those under 65 at increased risk of invasive pneumococcal disease.","length":248,"tagName":"p"},{"type":"text","conten...